Stem definition | Drug id | CAS RN |
---|---|---|
2274 | 58-38-8 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
50 | mg | P |
0.10 | g | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.83 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 15 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 22 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 9 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 23, 1956 | FDA | GLAXOSMITHKLINE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nausea | 353.75 | 11.64 | 1549 | 49912 | 754542 | 52543063 |
Febrile neutropenia | 320.78 | 11.64 | 448 | 51013 | 104488 | 53193117 |
Drug ineffective | 270.69 | 11.64 | 236 | 51225 | 817009 | 52480596 |
Disease progression | 257.71 | 11.64 | 398 | 51063 | 101522 | 53196083 |
Dehydration | 217.82 | 11.64 | 493 | 50968 | 167917 | 53129688 |
Diarrhoea | 198.68 | 11.64 | 1151 | 50310 | 624395 | 52673210 |
White blood cell count decreased | 198.58 | 11.64 | 397 | 51064 | 124078 | 53173527 |
Vomiting | 193.81 | 11.64 | 968 | 50493 | 496171 | 52801434 |
Plasma cell myeloma | 156.02 | 11.64 | 211 | 51250 | 47663 | 53249942 |
Platelet count decreased | 136.85 | 11.64 | 314 | 51147 | 107785 | 53189820 |
Fatigue | 135.78 | 11.64 | 1181 | 50280 | 729325 | 52568280 |
Rheumatoid arthritis | 124.09 | 11.64 | 75 | 51386 | 314456 | 52983149 |
Contraindicated product administered | 116.66 | 11.64 | 3 | 51458 | 135626 | 53161979 |
Neutropenia | 113.86 | 11.64 | 375 | 51086 | 158810 | 53138795 |
Death | 108.65 | 11.64 | 651 | 50810 | 356581 | 52941024 |
Constipation | 102.00 | 11.64 | 420 | 51041 | 197992 | 53099613 |
Malignant neoplasm progression | 99.68 | 11.64 | 216 | 51245 | 71325 | 53226280 |
Systemic lupus erythematosus | 91.37 | 11.64 | 8 | 51453 | 125406 | 53172199 |
Synovitis | 90.53 | 11.64 | 3 | 51458 | 107890 | 53189715 |
Asthenia | 87.65 | 11.64 | 599 | 50862 | 342991 | 52954614 |
Toxicity to various agents | 87.04 | 11.64 | 52 | 51409 | 219546 | 53078059 |
Arthropathy | 86.30 | 11.64 | 16 | 51445 | 141437 | 53156168 |
Blood magnesium decreased | 75.87 | 11.64 | 74 | 51387 | 11740 | 53285865 |
Decreased appetite | 75.21 | 11.64 | 407 | 51054 | 214567 | 53083038 |
Therapeutic product effect decreased | 74.98 | 11.64 | 15 | 51446 | 125640 | 53171965 |
Neutrophil count decreased | 73.89 | 11.64 | 153 | 51308 | 48945 | 53248660 |
Joint swelling | 73.26 | 11.64 | 71 | 51390 | 234567 | 53063038 |
Full blood count decreased | 69.43 | 11.64 | 100 | 51361 | 23929 | 53273676 |
Neuropathy peripheral | 66.60 | 11.64 | 235 | 51226 | 102952 | 53194653 |
Heart rate abnormal | 64.54 | 11.64 | 43 | 51418 | 3957 | 53293648 |
Hospice care | 62.68 | 11.64 | 50 | 51411 | 6080 | 53291525 |
Pleural effusion | 61.75 | 11.64 | 207 | 51254 | 88372 | 53209233 |
Akathisia | 61.34 | 11.64 | 57 | 51404 | 8514 | 53289091 |
Carbohydrate antigen 125 increased | 60.18 | 11.64 | 35 | 51426 | 2533 | 53295072 |
Thrombosis | 59.34 | 11.64 | 160 | 51301 | 60633 | 53236972 |
Abdominal pain | 58.66 | 11.64 | 435 | 51026 | 255468 | 53042137 |
Neoplasm progression | 58.24 | 11.64 | 104 | 51357 | 29815 | 53267790 |
Glossodynia | 57.72 | 11.64 | 13 | 51448 | 100278 | 53197327 |
Lymphadenitis | 54.99 | 11.64 | 34 | 51427 | 2751 | 53294854 |
Therapeutic product effect incomplete | 54.65 | 11.64 | 11 | 51450 | 91773 | 53205832 |
Condition aggravated | 53.29 | 11.64 | 131 | 51330 | 297003 | 53000602 |
Clostridium difficile infection | 50.54 | 11.64 | 94 | 51367 | 27799 | 53269806 |
Small intestinal obstruction | 50.47 | 11.64 | 72 | 51389 | 17075 | 53280530 |
Gangrene | 48.20 | 11.64 | 39 | 51422 | 4838 | 53292767 |
Completed suicide | 47.71 | 11.64 | 38 | 51423 | 138163 | 53159442 |
Pericarditis | 47.19 | 11.64 | 4 | 51457 | 64402 | 53233203 |
Arterial occlusive disease | 44.95 | 11.64 | 38 | 51423 | 5011 | 53292594 |
Thrombocytopenia | 43.38 | 11.64 | 255 | 51206 | 138472 | 53159133 |
Pancytopenia | 43.14 | 11.64 | 188 | 51273 | 90740 | 53206865 |
Neovascularisation | 43.14 | 11.64 | 18 | 51443 | 629 | 53296976 |
Injection site erythema | 42.51 | 11.64 | 11 | 51450 | 77238 | 53220367 |
Coma | 42.24 | 11.64 | 5 | 51456 | 61778 | 53235827 |
Colitis | 42.20 | 11.64 | 111 | 51350 | 41441 | 53256164 |
Injection site pain | 40.63 | 11.64 | 30 | 51431 | 113361 | 53184244 |
Treatment failure | 39.86 | 11.64 | 39 | 51422 | 128364 | 53169241 |
Red blood cell count decreased | 39.66 | 11.64 | 99 | 51362 | 35804 | 53261801 |
Maternal exposure during pregnancy | 38.99 | 11.64 | 56 | 51405 | 155583 | 53142022 |
Palmar-plantar erythrodysaesthesia syndrome | 38.13 | 11.64 | 72 | 51389 | 21534 | 53276071 |
Cytokine release syndrome | 38.03 | 11.64 | 43 | 51418 | 8086 | 53289519 |
Failure to thrive | 37.96 | 11.64 | 40 | 51421 | 6952 | 53290653 |
General physical health deterioration | 37.68 | 11.64 | 52 | 51409 | 146890 | 53150715 |
Pneumonitis | 37.13 | 11.64 | 88 | 51373 | 30800 | 53266805 |
Swelling | 36.84 | 11.64 | 81 | 51380 | 191024 | 53106581 |
Pain | 35.46 | 11.64 | 380 | 51081 | 588018 | 52709587 |
Infusion related reaction | 35.37 | 11.64 | 60 | 51401 | 155897 | 53141708 |
Intentional overdose | 34.34 | 11.64 | 11 | 51450 | 67194 | 53230411 |
Weight decreased | 34.34 | 11.64 | 362 | 51099 | 234586 | 53063019 |
Psoriasis | 33.93 | 11.64 | 21 | 51440 | 87068 | 53210537 |
Alopecia areata | 33.67 | 11.64 | 20 | 51441 | 1505 | 53296100 |
Blood creatine increased | 33.62 | 11.64 | 32 | 51429 | 4925 | 53292680 |
Pneumonia | 32.41 | 11.64 | 562 | 50899 | 406607 | 52890998 |
Hair texture abnormal | 31.71 | 11.64 | 28 | 51433 | 3914 | 53293691 |
Lower respiratory tract infection | 31.41 | 11.64 | 25 | 51436 | 90956 | 53206649 |
Drug intolerance | 31.29 | 11.64 | 98 | 51363 | 205395 | 53092210 |
Injection site reaction | 30.73 | 11.64 | 6 | 51455 | 51160 | 53246445 |
Hair colour changes | 30.62 | 11.64 | 24 | 51437 | 2845 | 53294760 |
Rectal cancer metastatic | 30.48 | 11.64 | 11 | 51450 | 258 | 53297347 |
Off label use | 30.45 | 11.64 | 300 | 51161 | 471912 | 52825693 |
Psoriatic arthropathy | 30.35 | 11.64 | 5 | 51456 | 48185 | 53249420 |
Hepatic enzyme increased | 30.06 | 11.64 | 47 | 51414 | 126148 | 53171457 |
Drug hypersensitivity | 30.01 | 11.64 | 389 | 51072 | 264853 | 53032752 |
Haemoglobin decreased | 28.92 | 11.64 | 229 | 51232 | 137078 | 53160527 |
Anaemia | 28.90 | 11.64 | 400 | 51061 | 276318 | 53021287 |
Taste disorder | 28.84 | 11.64 | 37 | 51424 | 7931 | 53289674 |
Blood potassium decreased | 27.69 | 11.64 | 94 | 51367 | 40366 | 53257239 |
Wound | 27.06 | 11.64 | 29 | 51432 | 91528 | 53206077 |
Muscle twitching | 26.85 | 11.64 | 53 | 51408 | 16373 | 53281232 |
Hypokalaemia | 26.74 | 11.64 | 172 | 51289 | 96345 | 53201260 |
Hypophagia | 26.61 | 11.64 | 78 | 51383 | 30984 | 53266621 |
Mucosal inflammation | 26.34 | 11.64 | 96 | 51365 | 42688 | 53254917 |
Mobility decreased | 26.27 | 11.64 | 21 | 51440 | 76250 | 53221355 |
Sepsis | 25.97 | 11.64 | 235 | 51226 | 146194 | 53151411 |
Overdose | 24.83 | 11.64 | 41 | 51420 | 107695 | 53189910 |
Dysgeusia | 24.49 | 11.64 | 94 | 51367 | 42837 | 53254768 |
Back pain | 24.19 | 11.64 | 338 | 51123 | 233909 | 53063696 |
Drug interaction | 24.18 | 11.64 | 119 | 51342 | 219210 | 53078395 |
Suicide attempt | 24.12 | 11.64 | 13 | 51448 | 58155 | 53239450 |
Asthma | 23.72 | 11.64 | 43 | 51418 | 108929 | 53188676 |
Injection site swelling | 23.58 | 11.64 | 6 | 51455 | 42622 | 53254983 |
Oral pain | 23.58 | 11.64 | 68 | 51393 | 26769 | 53270836 |
Hyponatraemia | 23.34 | 11.64 | 182 | 51279 | 108425 | 53189180 |
Gastric disorder | 23.26 | 11.64 | 73 | 51388 | 30092 | 53267513 |
Knee arthroplasty | 22.25 | 11.64 | 3 | 51458 | 33566 | 53264039 |
Lymphadenopathy | 22.03 | 11.64 | 81 | 51380 | 36174 | 53261431 |
Dry skin | 21.98 | 11.64 | 95 | 51366 | 45665 | 53251940 |
Cholestasis of pregnancy | 21.96 | 11.64 | 14 | 51447 | 1195 | 53296410 |
Exposure during pregnancy | 21.60 | 11.64 | 56 | 51405 | 124804 | 53172801 |
Weight increased | 21.40 | 11.64 | 113 | 51348 | 204454 | 53093151 |
Red cell distribution width increased | 21.22 | 11.64 | 34 | 51427 | 8926 | 53288679 |
Autoimmune nephritis | 20.96 | 11.64 | 9 | 51452 | 338 | 53297267 |
Folliculitis | 20.63 | 11.64 | 3 | 51458 | 31706 | 53265899 |
C-reactive protein increased | 20.62 | 11.64 | 21 | 51440 | 67865 | 53229740 |
Hypoxia | 20.49 | 11.64 | 107 | 51354 | 55573 | 53242032 |
Tumour marker increased | 20.37 | 11.64 | 22 | 51439 | 3931 | 53293674 |
Pyrexia | 20.12 | 11.64 | 520 | 50941 | 402673 | 52894932 |
Musculoskeletal stiffness | 20.08 | 11.64 | 57 | 51404 | 123311 | 53174294 |
Discomfort | 19.61 | 11.64 | 39 | 51422 | 95433 | 53202172 |
Deep vein thrombosis | 19.53 | 11.64 | 142 | 51319 | 82771 | 53214834 |
Skull fracture | 19.38 | 11.64 | 12 | 51449 | 973 | 53296632 |
Irritable bowel syndrome | 19.22 | 11.64 | 9 | 51452 | 43623 | 53253982 |
Plasma cell myeloma recurrent | 19.08 | 11.64 | 18 | 51443 | 2739 | 53294866 |
Madarosis | 18.68 | 11.64 | 18 | 51443 | 2812 | 53294793 |
Abortion spontaneous | 18.50 | 11.64 | 11 | 51450 | 46624 | 53250981 |
Skin exfoliation | 18.17 | 11.64 | 76 | 51385 | 36007 | 53261598 |
Coronary artery disease | 17.94 | 11.64 | 5 | 51456 | 33432 | 53264173 |
Laboratory test abnormal | 17.85 | 11.64 | 58 | 51403 | 24351 | 53273254 |
Loss of personal independence in daily activities | 17.59 | 11.64 | 25 | 51436 | 69790 | 53227815 |
Acquired cystic kidney disease | 17.52 | 11.64 | 5 | 51456 | 53 | 53297552 |
Red blood cell sedimentation rate increased | 17.47 | 11.64 | 3 | 51458 | 28054 | 53269551 |
Mental status changes | 17.39 | 11.64 | 80 | 51381 | 39491 | 53258114 |
Parkinsonism | 17.11 | 11.64 | 31 | 51430 | 8982 | 53288623 |
Hypermagnesaemia | 16.69 | 11.64 | 11 | 51450 | 994 | 53296611 |
Fibromyalgia | 16.65 | 11.64 | 11 | 51450 | 44064 | 53253541 |
Arthralgia | 16.48 | 11.64 | 312 | 51149 | 439471 | 52858134 |
Paradoxical drug reaction | 16.26 | 11.64 | 18 | 51443 | 3307 | 53294298 |
Injection site pruritus | 16.23 | 11.64 | 10 | 51451 | 41579 | 53256026 |
Injection site bruising | 16.22 | 11.64 | 8 | 51453 | 37638 | 53259967 |
Morbid thoughts | 16.08 | 11.64 | 9 | 51452 | 605 | 53297000 |
Drug reaction with eosinophilia and systemic symptoms | 15.67 | 11.64 | 6 | 51455 | 32794 | 53264811 |
Pancreatic carcinoma recurrent | 15.58 | 11.64 | 5 | 51456 | 81 | 53297524 |
Nasopharyngitis | 15.56 | 11.64 | 115 | 51346 | 192180 | 53105425 |
Clostridium difficile colitis | 15.39 | 11.64 | 48 | 51413 | 19717 | 53277888 |
Ill-defined disorder | 15.35 | 11.64 | 15 | 51446 | 49429 | 53248176 |
Ovarian cancer recurrent | 15.24 | 11.64 | 11 | 51450 | 1152 | 53296453 |
Pulmonary embolism | 15.15 | 11.64 | 173 | 51288 | 114269 | 53183336 |
Multiple sclerosis relapse | 14.64 | 11.64 | 13 | 51448 | 44840 | 53252765 |
Pregnancy | 14.61 | 11.64 | 6 | 51455 | 31435 | 53266170 |
Blood pressure fluctuation | 14.60 | 11.64 | 8 | 51453 | 35462 | 53262143 |
Cardiac failure | 14.46 | 11.64 | 39 | 51422 | 85805 | 53211800 |
Dyssomnia | 14.32 | 11.64 | 4 | 51457 | 39 | 53297566 |
Streptococcal bacteraemia | 14.26 | 11.64 | 12 | 51449 | 1572 | 53296033 |
Stomatitis | 14.19 | 11.64 | 151 | 51310 | 98007 | 53199598 |
Lymphocyte count decreased | 14.06 | 11.64 | 59 | 51402 | 27993 | 53269612 |
Neutropenic sepsis | 13.73 | 11.64 | 38 | 51423 | 14611 | 53282994 |
Oesophagitis | 13.68 | 11.64 | 38 | 51423 | 14639 | 53282966 |
Chills | 13.66 | 11.64 | 158 | 51303 | 104690 | 53192915 |
Dizziness | 13.62 | 11.64 | 462 | 50999 | 371797 | 52925808 |
Enteritis | 13.37 | 11.64 | 25 | 51436 | 7421 | 53290184 |
Lymph node pain | 13.29 | 11.64 | 11 | 51450 | 1409 | 53296196 |
Drug abuse | 13.25 | 11.64 | 27 | 51434 | 65499 | 53232106 |
Embolism | 13.23 | 11.64 | 25 | 51436 | 7478 | 53290127 |
Intentional self-injury | 13.16 | 11.64 | 4 | 51457 | 25280 | 53272325 |
Acute myeloid leukaemia | 13.08 | 11.64 | 41 | 51420 | 16891 | 53280714 |
Hypersensitivity | 13.05 | 11.64 | 135 | 51326 | 210530 | 53087075 |
Therapeutic response decreased | 13.04 | 11.64 | 16 | 51445 | 47553 | 53250052 |
Heart rate decreased | 12.94 | 11.64 | 10 | 51451 | 36937 | 53260668 |
Inflammation | 12.92 | 11.64 | 22 | 51439 | 57114 | 53240491 |
Diabetes mellitus | 12.89 | 11.64 | 20 | 51441 | 53879 | 53243726 |
Abdominal discomfort | 12.75 | 11.64 | 144 | 51317 | 220918 | 53076687 |
Plasmacytoma | 12.67 | 11.64 | 14 | 51447 | 2567 | 53295038 |
Haematocrit decreased | 12.55 | 11.64 | 70 | 51391 | 37261 | 53260344 |
Osteonecrosis | 12.47 | 11.64 | 5 | 51456 | 26570 | 53271035 |
Hypomagnesaemia | 12.29 | 11.64 | 52 | 51409 | 24759 | 53272846 |
Enterocolitis infectious | 12.15 | 11.64 | 11 | 51450 | 1589 | 53296016 |
Intentional product misuse | 12.13 | 11.64 | 18 | 51443 | 49374 | 53248231 |
Urinary tract infection | 12.11 | 11.64 | 310 | 51151 | 239593 | 53058012 |
Wrong technique in product usage process | 11.92 | 11.64 | 25 | 51436 | 60007 | 53237598 |
Product quality issue | 11.77 | 11.64 | 11 | 51450 | 37012 | 53260593 |
Ascites | 11.73 | 11.64 | 72 | 51389 | 39663 | 53257942 |
Cataract | 11.69 | 11.64 | 85 | 51376 | 49535 | 53248070 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 319.02 | 12.59 | 495 | 32978 | 119071 | 32360982 |
Nausea | 235.05 | 12.59 | 793 | 32680 | 320056 | 32159997 |
Fatigue | 177.53 | 12.59 | 771 | 32702 | 349930 | 32130123 |
Disease progression | 137.68 | 12.59 | 287 | 33186 | 86575 | 32393478 |
Plasma cell myeloma | 125.45 | 12.59 | 218 | 33255 | 57396 | 32422657 |
Dehydration | 122.75 | 12.59 | 350 | 33123 | 128608 | 32351445 |
Malignant neoplasm progression | 97.02 | 12.59 | 235 | 33238 | 78261 | 32401792 |
Diarrhoea | 93.53 | 12.59 | 668 | 32805 | 364134 | 32115919 |
Vomiting | 93.16 | 12.59 | 483 | 32990 | 235074 | 32244979 |
Death | 92.68 | 12.59 | 691 | 32782 | 381826 | 32098227 |
Pneumonia | 87.28 | 12.59 | 644 | 32829 | 354608 | 32125445 |
Decreased appetite | 79.60 | 12.59 | 352 | 33121 | 160461 | 32319592 |
Drug interaction | 68.80 | 12.59 | 74 | 33399 | 218111 | 32261942 |
White blood cell count decreased | 64.92 | 12.59 | 224 | 33249 | 90974 | 32389079 |
Drug abuse | 63.68 | 12.59 | 5 | 33468 | 80238 | 32399815 |
Toxicity to various agents | 58.79 | 12.59 | 58 | 33415 | 177983 | 32302070 |
Neuropathy peripheral | 58.23 | 12.59 | 193 | 33280 | 76789 | 32403264 |
Full blood count decreased | 56.09 | 12.59 | 78 | 33395 | 16932 | 32463121 |
Drug ineffective | 53.38 | 12.59 | 209 | 33264 | 383268 | 32096785 |
Constipation | 53.19 | 12.59 | 264 | 33209 | 126109 | 32353944 |
Platelet count decreased | 50.80 | 12.59 | 243 | 33230 | 114348 | 32365705 |
Condition aggravated | 48.78 | 12.59 | 53 | 33420 | 155608 | 32324445 |
Neutropenia | 43.78 | 12.59 | 273 | 33200 | 141902 | 32338151 |
Completed suicide | 41.09 | 12.59 | 22 | 33451 | 92495 | 32387558 |
Small intestinal obstruction | 39.38 | 12.59 | 60 | 33413 | 14136 | 32465917 |
Overdose | 38.24 | 12.59 | 21 | 33452 | 87056 | 32392997 |
Neutrophil count decreased | 38.16 | 12.59 | 121 | 33352 | 47018 | 32433035 |
Failure to thrive | 37.74 | 12.59 | 45 | 33428 | 8390 | 32471663 |
Cytokine release syndrome | 37.26 | 12.59 | 57 | 33416 | 13478 | 32466575 |
Neoplasm progression | 37.14 | 12.59 | 70 | 33403 | 19588 | 32460465 |
Hospice care | 37.06 | 12.59 | 36 | 33437 | 5323 | 32474730 |
Rash | 36.99 | 12.59 | 353 | 33120 | 208980 | 32271073 |
Back pain | 33.38 | 12.59 | 212 | 33261 | 110841 | 32369212 |
Psoriasis | 31.26 | 12.59 | 5 | 33468 | 46118 | 32433935 |
Deep vein thrombosis | 30.31 | 12.59 | 138 | 33335 | 63575 | 32416478 |
Muscle spasms | 30.21 | 12.59 | 148 | 33325 | 70270 | 32409783 |
Asthenia | 30.14 | 12.59 | 373 | 33100 | 235571 | 32244482 |
Therapeutic product effect incomplete | 29.13 | 12.59 | 4 | 33469 | 41337 | 32438716 |
Intentional overdose | 27.11 | 12.59 | 5 | 33468 | 41596 | 32438457 |
Product use in unapproved indication | 26.95 | 12.59 | 30 | 33443 | 87174 | 32392879 |
Sepsis | 26.13 | 12.59 | 264 | 33209 | 158570 | 32321483 |
Rheumatoid arthritis | 25.72 | 12.59 | 7 | 33466 | 44537 | 32435516 |
Thrombosis | 25.52 | 12.59 | 104 | 33369 | 45650 | 32434403 |
Adverse drug reaction | 25.30 | 12.59 | 71 | 33402 | 25790 | 32454263 |
Bradycardia | 25.12 | 12.59 | 22 | 33451 | 71540 | 32408513 |
Rhabdomyolysis | 24.45 | 12.59 | 20 | 33453 | 67245 | 32412808 |
Ageusia | 24.13 | 12.59 | 39 | 33434 | 9663 | 32470390 |
Pulmonary embolism | 24.07 | 12.59 | 158 | 33315 | 83501 | 32396552 |
Suicide attempt | 24.07 | 12.59 | 5 | 33468 | 38239 | 32441814 |
Coma | 24.04 | 12.59 | 7 | 33466 | 42605 | 32437448 |
General physical health deterioration | 23.83 | 12.59 | 52 | 33421 | 115207 | 32364846 |
Laboratory test abnormal | 23.37 | 12.59 | 57 | 33416 | 19030 | 32461023 |
Cardiac failure | 22.78 | 12.59 | 37 | 33436 | 91636 | 32388417 |
Intentional product misuse | 22.11 | 12.59 | 5 | 33468 | 36046 | 32444007 |
Spinal cord compression | 21.42 | 12.59 | 23 | 33450 | 3826 | 32476227 |
Wrong technique in product usage process | 21.23 | 12.59 | 5 | 33468 | 35054 | 32444999 |
Oral pain | 20.70 | 12.59 | 37 | 33436 | 9941 | 32470112 |
Coronary artery disease | 20.38 | 12.59 | 13 | 33460 | 49693 | 32430360 |
Dysgeusia | 20.16 | 12.59 | 65 | 33408 | 25466 | 32454587 |
Off label use | 20.14 | 12.59 | 210 | 33263 | 306110 | 32173943 |
Hyponatraemia | 19.80 | 12.59 | 138 | 33335 | 74375 | 32405678 |
Injection site pain | 19.46 | 12.59 | 5 | 33468 | 33053 | 32447000 |
C-reactive protein increased | 19.15 | 12.59 | 13 | 33460 | 48089 | 32431964 |
Drug reaction with eosinophilia and systemic symptoms | 18.95 | 12.59 | 5 | 33468 | 32480 | 32447573 |
Hiccups | 18.39 | 12.59 | 35 | 33438 | 9860 | 32470193 |
Weight decreased | 17.85 | 12.59 | 253 | 33220 | 164565 | 32315488 |
Hypophagia | 16.75 | 12.59 | 58 | 33415 | 23565 | 32456488 |
Mental status changes | 16.73 | 12.59 | 81 | 33392 | 38256 | 32441797 |
Treatment failure | 16.39 | 12.59 | 10 | 33463 | 39153 | 32440900 |
Diaphragmatic rupture | 16.37 | 12.59 | 4 | 33469 | 20 | 32480033 |
Plasma cell myeloma recurrent | 16.23 | 12.59 | 20 | 33453 | 3857 | 32476196 |
Bacteraemia | 15.88 | 12.59 | 47 | 33426 | 17586 | 32462467 |
Pleural effusion | 15.82 | 12.59 | 137 | 33336 | 78855 | 32401198 |
Immune effector cell-associated neurotoxicity syndrome | 15.74 | 12.59 | 13 | 33460 | 1555 | 32478498 |
Bacillus bacteraemia | 15.37 | 12.59 | 5 | 33468 | 79 | 32479974 |
Foetal exposure during pregnancy | 15.35 | 12.59 | 12 | 33461 | 41289 | 32438764 |
Oesophagitis | 15.08 | 12.59 | 38 | 33435 | 12943 | 32467110 |
Inappropriate schedule of product administration | 15.01 | 12.59 | 15 | 33458 | 45810 | 32434243 |
Asthma | 14.92 | 12.59 | 14 | 33459 | 44051 | 32436002 |
Clostridium difficile infection | 14.68 | 12.59 | 46 | 33427 | 17750 | 32462303 |
Mixed dementia | 14.62 | 12.59 | 7 | 33466 | 318 | 32479735 |
Inferior vena caval occlusion | 14.45 | 12.59 | 4 | 33469 | 35 | 32480018 |
Dystonia | 14.39 | 12.59 | 33 | 33440 | 10590 | 32469463 |
Tooth disorder | 14.36 | 12.59 | 32 | 33441 | 10075 | 32469978 |
Cholestasis | 14.26 | 12.59 | 5 | 33468 | 27028 | 32453025 |
Temperature intolerance | 14.13 | 12.59 | 17 | 33456 | 3198 | 32476855 |
Hypoxia | 14.11 | 12.59 | 97 | 33376 | 52035 | 32428018 |
Wrist deformity | 14.07 | 12.59 | 7 | 33466 | 346 | 32479707 |
Haematochezia | 13.82 | 12.59 | 12 | 33461 | 39196 | 32440857 |
Enterocolitis infectious | 13.75 | 12.59 | 11 | 33462 | 1257 | 32478796 |
Seizure | 13.48 | 12.59 | 58 | 33415 | 103796 | 32376257 |
Mucosal inflammation | 13.43 | 12.59 | 69 | 33404 | 33365 | 32446688 |
Pneumonitis | 13.39 | 12.59 | 64 | 33409 | 30070 | 32449983 |
Myocardial infarction | 12.99 | 12.59 | 76 | 33397 | 125600 | 32354453 |
Drug dependence | 12.99 | 12.59 | 4 | 33469 | 23480 | 32456573 |
Electrocardiogram QT prolonged | 12.95 | 12.59 | 13 | 33460 | 39628 | 32440425 |
Cholangiocarcinoma | 12.94 | 12.59 | 10 | 33463 | 1087 | 32478966 |
Anaemia | 12.85 | 12.59 | 311 | 33162 | 223313 | 32256740 |
Meconium abnormal | 12.82 | 12.59 | 3 | 33470 | 12 | 32480041 |
Pancytopenia | 12.81 | 12.59 | 147 | 33326 | 91088 | 32388965 |
Oral candidiasis | 12.73 | 12.59 | 34 | 33439 | 11993 | 32468060 |
Respiratory arrest | 12.64 | 12.59 | 7 | 33466 | 28901 | 32451152 |
Source | Code | Description |
---|---|---|
ATC | N05AB04 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure |
FDA CS | M0016525 | Phenothiazines |
MeSH PA | D000932 | Antiemetics |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:37890 | alpha-adrenoceptor antagonists |
CHEBI has role | CHEBI:48561 | dopamine blocker |
CHEBI has role | CHEBI:48873 | Anticholinergika |
CHEBI has role | CHEBI:50919 | antiemetico |
CHEBI has role | CHEBI:65190 | typical antipsychotic drug |
CHEBI has role | CHEBI:76779 | prolyl oligopeptidase (EC 3.4.21.26) inhibitor |
CHEBI has role | CHEBI:131787 | D2 receptor antagonist |
FDA EPC | N0000175746 | Phenothiazine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Nausea and vomiting | indication | 16932000 | |
Schizophrenia | indication | 58214004 | DOID:5419 |
Nonpsychotic Anxiety | indication | ||
Prolonged-Severe Nausea and Vomiting | indication | ||
Migraine | off-label use | 37796009 | DOID:6364 |
Chemotherapy-induced nausea and vomiting | off-label use | 236084000 | |
Brain damage | contraindication | 2470005 | |
Tachyarrhythmia | contraindication | 6285003 | |
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Alcoholism | contraindication | 7200002 | |
Organophosphate poisoning | contraindication | 8260003 | |
Weight gain finding | contraindication | 8943002 | |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Senile dementia | contraindication | 15662003 | |
Chronic disease of respiratory system | contraindication | 17097001 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Orthostatic hypotension | contraindication | 28651003 | |
Atony of colon | contraindication | 29479008 | |
Torsades de pointes | contraindication | 31722008 | |
Parkinsonism | contraindication | 32798002 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
Conduction disorder of the heart | contraindication | 44808001 | |
Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
Chronic heart failure | contraindication | 48447003 | |
Bradycardia | contraindication | 48867003 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Peptic reflux disease | contraindication | 57643001 | |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
Extrapyramidal disease | contraindication | 76349003 | |
Spastic paralysis | contraindication | 78403003 | |
Disturbance of salivary secretion | contraindication | 78948009 | |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Stupor | contraindication | 89458003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Tardive dyskinesia | contraindication | 102449007 | |
Prolonged QT interval | contraindication | 111975006 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Acute disease of cardiovascular system | contraindication | 128487001 | |
Autonomic dysreflexia | contraindication | 129618003 | |
Bleeding | contraindication | 131148009 | |
Angina pectoris | contraindication | 194828000 | |
Myocardial dysfunction | contraindication | 233928007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
Pyloric obstruction | contraindication | 244815007 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Drowsy | contraindication | 271782001 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Coma | contraindication | 371632003 | |
At risk for aspiration | contraindication | 371736008 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Visual impairment | contraindication | 397540003 | |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Obesity | contraindication | 414916001 | DOID:9970 |
Congenital long QT syndrome | contraindication | 442917000 | |
Carcinoma of female breast | contraindication | 447782002 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.74 | Basic |
pKa2 | 4.74 | Basic |
pKa3 | 2.21 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.76 | WOMBAT-PK | CHEMBL | |||
D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.61 | WOMBAT-PK | IUPHAR | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 7.20 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.64 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | Ki | 5.82 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.21 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.40 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.23 | PDSP | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 7.82 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.19 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.91 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.91 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 7.62 | WOMBAT-PK | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 8.32 | DRUG MATRIX | |||||
Histamine H1 receptor | GPCR | Ki | 7.72 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.61 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.96 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.49 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.72 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.80 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.92 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.86 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 7.17 | WOMBAT-PK | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 7.89 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.25 | DRUG MATRIX | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.30 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 7.11 | DRUG MATRIX | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.31 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.92 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.38 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.49 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.02 | CHEMBL | |||||
5-hydroxytryptamine receptor 4 | GPCR | Ki | 6.71 | DRUG MATRIX | |||||
Pleiotropic ABC efflux transporter of multiple drugs | Transporter | IC50 | 5.77 | CHEMBL |
ID | Source |
---|---|
4018001 | VUID |
N0000146346 | NUI |
D00479 | KEGG_DRUG |
84-02-6 | SECONDARY_CAS_RN |
4017999 | VANDF |
4018000 | VANDF |
4018001 | VANDF |
C0033229 | UMLSCUI |
CHEBI:8435 | CHEBI |
P77 | PDB_CHEM_ID |
CHEMBL728 | ChEMBL_ID |
CHEMBL1200587 | ChEMBL_ID |
CHEMBL1314751 | ChEMBL_ID |
DB00433 | DRUGBANK_ID |
CHEMBL1201154 | ChEMBL_ID |
D011346 | MESH_DESCRIPTOR_UI |
4917 | PUBCHEM_CID |
7279 | IUPHAR_LIGAND_ID |
699 | INN_ID |
YHP6YLT61T | UNII |
235739 | RXNORM |
2073 | MMSL |
5361 | MMSL |
5362 | MMSL |
5363 | MMSL |
6416 | MMSL |
6417 | MMSL |
d00355 | MMSL |
001478 | NDDF |
001479 | NDDF |
001480 | NDDF |
003466 | NDDF |
22827004 | SNOMEDCT_US |
372853006 | SNOMEDCT_US |
3823007 | SNOMEDCT_US |
395843006 | SNOMEDCT_US |
79129001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5105 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5110 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 14 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-8190 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Compro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-7226 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 19 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6135 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 18 sections |
Prochlorperazine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0135 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 13 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0351 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5020 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 18 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5021 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 18 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-281 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-511 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-700 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 18 sections |
PROCHLORPERAZINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-327 | TABLET | 10 mg | ORAL | ANDA | 10 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-571 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-572 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-294 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
PROCHLORPERAZINE EDISYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-497 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 12 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-523 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
PROCHLORPERAZINE EDISYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-790 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 18 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-141 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-550 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-728 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-729 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Prochlorperazine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42708-103 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-353 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-742 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE EDISYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-090 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 18 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0109 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0110 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
Prochlorperazine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0636 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 13 sections |